Is Intellia Therapeutics, Inc. overvalued or undervalued?

As of 14 March 2017, the valuation grade for Intellia Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued given its negative performance metrics and ratios. Key ratios include a Price to Book Value of 1.07, an EV to Sales ratio of 8.19, and a ROCE of -169.74%, which highlight significant operational challenges.
In comparison to its peers, Intellia's P/E ratio is notably negative at -2.7230, while BridgeBio Pharma, Inc. has a P/E of -14.1231, and CRISPR Therapeutics AG stands at -13.2694, indicating that Intellia is not alone in facing valuation difficulties, but it still lags behind in terms of relative performance. Despite a strong short-term stock return of 41.07% over the past week compared to the S&P 500's 1.05%, the longer-term outlook remains bleak, with a 3-year return of -75.48% against the S&P 500's 70.41%.